JITC Digest October 2018

jitc-logo.gif

Inside this Issue:

Letter from the Editor

Dear JITC Readers,pedro-romero_1__1_.jpg

The Journal for ImmunoTherapy of Cancer (JITC) congratulates James P. Allison, PhD, and Tasuku Honjo, MD, PhD, on their recognition as 2018 recipients of the Nobel Prize for their scientific contributions to the emerging field of immune checkpoint blockade therapy. Their work in the lab has become a foundational component of cancer treatment across the globe. The honor draws light on the innovation and collaboration of cancer researchers allowing the science to advance rapidly in the lab and into the clinic where many patients are now benefiting from these breakthroughs. I look forward to seeing where this continued momentum takes us as we work toward making the word “cure” a reality for patients everywhere.

In the October edition of the JITC Digest, there are four articles of special significance of which I wish to draw special attention. First, “Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy,” by Guozhu Xie et al. demonstrates the role of local angiotensin II (AngII) in establishing an immunosuppressive tumor microenvironment. In this research article, Dr. Xie’s team describes a novel mechanism for enhancing tumor response to checkpoint blockade immunotherapy through blockage of AngII signaling.

Next, Jason M. Redman et al.’s clinical trials monitor article, “Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer,” presents the QuEST1 study, an open and accruing adaptive-design clinical trial evaluating various combination therapies in metastatic castration-resistant prostate cancer (mCRPC). QuEST1 aims to expedite investigation of multimodal immunotherapy in mCRPC, a disease with low response rates to single agent immune checkpoint inhibitors.

Maartje W. Rohaan et al.’s review, “Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option,” provides an authoritative overview of the current state of adoptive cell therapy with tumor infiltrating lymphocytes (TILs) in melanoma patients. Specifically, this article provides a detailed account of the applicability and hurdles of developing TIL immunotherapy, including clinical response, production and treatment strategies, toxicity, and the future potential of TIL therapy as part of both monotherapy and combination therapy anti-tumor treatment regimens.

Finally, the article, “A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy,” by Jingjing Duan et al. presents a novel model for predicting prognosis in esophageal squamous cell carcinoma (ESCC) patients based on independent prognostic immune variables. This comprehensive, nomogram-based immunoprofile developed by Dr. Duan’s team appears apt to complement the TNM system for survival prediction in operable ESCC patients.

With best regards,
Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer


Recent Articles

Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

Daniel H Johnson, Chrystia M Zobniw, Van A Trinh, Junsheng Ma, Roland L BassettJr, Noha Abdel-Wahab, Jaime Anderson, Jennifer E Davis, Jocelyn Joseph, Marc Uemura, Ali Noman, Hamzah Abu-Sbeih, Cassian Yee, Rodabe Amaria, Sapna Patel, Hussein Tawbi, Isabella C Glitza, Michael A Davies, Michael K Wong, Scott Woodman, Wen-Jen Hwu, Patrick Hwu, Yinghong Wang and Adi Diab
Journal for ImmunoTherapy of Cancer, 6:103 (11 October 2018)
Research Article

Excerpt:

"Our study provides much-needed data supporting the early use of IFX [infliximab] to hasten irEC [immune-related enterocolitis] symptom resolution, particularly in patients with high-grade colitis."

Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

Daniel H Johnson, Chrystia M Zobniw, Van A Trinh, Junsheng Ma, Roland L BassettJr, Noha Abdel-Wahab, Jaime Anderson, Jennifer E Davis, Jocelyn Joseph, Marc Uemura, Ali Noman, Hamzah Abu-Sbeih, Cassian Yee, Rodabe Amaria, Sapna Patel, Hussein Tawbi, Isabella C Glitza, Michael A Davies, Michael K Wong, Scott Woodman, Wen-Jen Hwu, Patrick Hwu, Yinghong Wang and Adi Diab
Journal for ImmunoTherapy of Cancer, 6:103 (11 October 2018)
Research Article

Excerpt:

"Our study provides much-needed data supporting the early use of IFX [infliximab] to hasten irEC [immune-related enterocolitis] symptom resolution, particularly in patients with high-grade colitis."

Guozhu Xie, MD, PhD — Southern Medical University Nanfang Hospital


Highly Accessed Articles

SITC_logo.jpg

Resident memory T cells, critical components in tumor immunology

Fathia Mami-Chouaib, Charlotte Blanc, Stéphanie Corgnac, Sophie Hans, Ines Malenica, Clémence Granier, Isabelle Tihy and Eric Tartour
Journal for ImmunoTherapy of Cancer 2018, 6:87 (4 September 2018)

SITC_logo.jpg

Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity

Orneala Bakos, Christine Lawson, Samuel Rouleau and Lee-Hwa Tai
Journal for ImmunoTherapy of Cancer 2018, 6:86 (3 September 2018)

SITC_logo.jpg

White paper on microbial anti-cancer therapy and prevention

Neil S. Forbes, Robert S. Coffin, Liang Deng, Laura Evgin, Steve Fiering, Matthew Giacalone, Claudia Gravekamp, James L. Gulley, Hal Gunn, Robert M. Hoffman, Balveen Kaur, Ke Liu, Herbert Kim Lyerly, Ariel E. Marciscano, Eddie Moradian, Sheryl Ruppel, Daniel A. Saltzman, Peter J. Tattersall, Steve Thorne, Richard G. Vile, Halle Huihong Zhang, Shibin Zhou and Grant McFadden
Journal for ImmunoTherapy of Cancer 2018, 6:78 (6 August 2018)


Submit Your Research to JITC

SITC Members Receive Complimentary Article Processing Charges in 2018*
SITC members and non-members are invited to submit manuscripts to the society's official journal.
Article Types
JITC Editor-in-Chief
Pedro J. Romero, MD – University of Lausanne

Section Editors

  • Basic Tumor Immunology: Cornelis J.M. Melief, MD, PhD – ISA Therapeutics BV
  • Case Reports: Alfred Zippelius, MD – University Hospital Basel
  • Clinical/Translational Cancer Immunology: James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Health
  • Clinical Trials Monitor: Leisha A. Emens, MD, PhD – Johns Hopkins University
  • Commentary/Editorials: Christian Capitini, MD – University of Wisconsin - Madison
  • Guidelines and Consensus Statements: Robert L. Ferris, MD, PhD – University of Pittsburgh Cancer Institute
  • Immunotherapy Biomarkers: Lisa H. Butterfield, PhD – University of Pittsburgh Cancer Institute
  • Reviews: Sandra Demaria, MD – Weill Cornell Medical College; Thomas F. Gajewski, MD, PhD – University of Chicago

To view the full editorial board, please click here.

*As a way to thank the dedicated society members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, one article per SITC member is eligible for waived article processing charges through 2018. To take advantage of this benefit valued at more than $2,400, authors must contact JITC Managing Editor Andrea Rindo at JITCEditor@sitcancer.org or 1-414-271-2456 prior to submission to obtain a discount code and instructions.

Join_SITC_JITC.png?r=1499893816711 Become a Member!

Journal for ImmunoTherapy of Cancer (JITC) is the official, online, open access journal of the Society for Immunotherapy of Cancer (SITC) and considered BMC’s premier cancer immunotherapy journal. JITC welcomes basic, translational and clinical research and literature reviews on any aspect of tumor immunology and cancer immunotherapy. Topics of interest include tumor-host interactions, immune biomarkers, novel therapeutics, and immune-related toxicity.  The journal’s full collection, including its seminal guidelines and consensus statements, advances the rapidly evolving field of cancer immunotherapy through dissemination of rigorous peer-reviewed research.